BioXcel Therapeutics (BTAI) Finished Goods (2022 - 2026)

BioXcel Therapeutics' Finished Goods history runs 5 years deep, the most recent figure standing at $92000.0 for Q1 2026.

• On a quarterly basis, Finished Goods fell 48.31% year-over-year to $92000.0 in Q1 2026; TTM through Mar 2026 was $92000.0, a 48.31% decrease from a year earlier, with the FY2025 full-year figure at $37000.0, down 78.61% from the prior year.
• Finished Goods advanced to $92000.0 in Q1 2026 per BTAI's latest filing, from $37000.0 in the prior quarter.
• Across five years, Finished Goods topped out at $1.4 million in Q2 2024 and bottomed at $37000.0 in Q4 2025.
• The 5-year median for Finished Goods is $500000.0 (2022), against an average of $572437.5.
• Across the five-year window, Finished Goods soared 314.33% in 2023 and plunged 94.97% in 2025, its largest moves.
• Year by year, Finished Goods stood at $595000.0 in 2022, then slumped by 31.93% to $405000.0 in 2023, then plunged by 57.28% to $173000.0 in 2024, then tumbled by 78.61% to $37000.0 in 2025, then soared by 148.65% to $92000.0 in 2026.
• Per Business Quant, the three latest BTAI Finished Goods figures stand at $92000.0 (Q1 2026), $37000.0 (Q4 2025), and $65000.0 (Q3 2025).